Replies to post #19 on Albany Molecular Research, Inc. (AMRI)

[surf1944]

8:04AM Albany Molecular misses by $0.03, beats on revs; guides FY12 EPS in-line (AMRI) 3.01 : Reports Q1 (Mar) earnings of $0.02 per share, $0.03 worse than the Capital IQ Consensus Estimate of $0.05; revenues fell 5.6% year/year to $53.7 mln vs the $52.12 mln consensus. Co issues in-line guidance for FY12, sees EPS of $0.06-0.12 vs. $0.09 Capital IQ Consensus Estimate. "In the second quarter, we expect contract revenue to range from $40 million to $43 million. For the full year 2012, we continue to expect contract revenue to range from $176 million to $186 million, an increase of up to 10% versus 2011... We expect second quarter royalties of $8 to $9 million and full year 2012 royalties of $32 to $36 million. We are raising our contract gross margin estimate for the year to range from 6-10% but anticipate variability between the quarters related to mix."